Vincent Lok, Sy Olson-McPeek, Grace Spiegelhoff, Jaqueline Cortez, David Detz, Brian Czerniecki
{"title":"乳腺癌的免疫疗法：利用癌症免疫循环。","authors":"Vincent Lok, Sy Olson-McPeek, Grace Spiegelhoff, Jaqueline Cortez, David Detz, Brian Czerniecki","doi":"10.1080/14728222.2024.2427038","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Immunotherapies have found limited success in breast cancerdue to significant challenges within the tumor that block T-cell activity and function.</p><p><strong>Areas covered: </strong>The current review discusses clinically relevant immunotherapeutics and trials within the framework of the cancer-immunity cycle.</p><p><strong>Expert opinion: </strong>Current therapies such as antibody-drug conjugates and immune checkpoint blockade require proper biomarker selection, such as PD1 expression and the degree of tumor-infiltrating lymphocyte (TIL) infiltration to subset potential responders. HER2 and other tumor-associated antigens have served as valuable benchmarks for developing novel therapies, such as antibody engagers and CAR T-cells. However, further research is essential to identify and validate new target antigens that can enhance therapeutic efficacy and broaden the clinical applicability of these approaches.</p>","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"1-11"},"PeriodicalIF":4.6000,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immunotherapies in breast cancer: harnessing the cancer immunity cycle.\",\"authors\":\"Vincent Lok, Sy Olson-McPeek, Grace Spiegelhoff, Jaqueline Cortez, David Detz, Brian Czerniecki\",\"doi\":\"10.1080/14728222.2024.2427038\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Immunotherapies have found limited success in breast cancerdue to significant challenges within the tumor that block T-cell activity and function.</p><p><strong>Areas covered: </strong>The current review discusses clinically relevant immunotherapeutics and trials within the framework of the cancer-immunity cycle.</p><p><strong>Expert opinion: </strong>Current therapies such as antibody-drug conjugates and immune checkpoint blockade require proper biomarker selection, such as PD1 expression and the degree of tumor-infiltrating lymphocyte (TIL) infiltration to subset potential responders. HER2 and other tumor-associated antigens have served as valuable benchmarks for developing novel therapies, such as antibody engagers and CAR T-cells. However, further research is essential to identify and validate new target antigens that can enhance therapeutic efficacy and broaden the clinical applicability of these approaches.</p>\",\"PeriodicalId\":12185,\"journal\":{\"name\":\"Expert Opinion on Therapeutic Targets\",\"volume\":\" \",\"pages\":\"1-11\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-11-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Therapeutic Targets\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14728222.2024.2427038\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14728222.2024.2427038","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
简介：免疫疗法在乳腺癌中的成功率有限，原因是肿瘤内部存在阻碍T细胞活性和功能的重大挑战：本综述在癌症-免疫循环的框架内讨论了临床相关的免疫疗法和试验：目前的疗法，如抗体药物共轭物和免疫检查点阻断，需要适当的生物标记物选择，如PD1表达和肿瘤浸润淋巴细胞（TIL）浸润程度，以细分潜在的应答者。HER2 和其他肿瘤相关抗原已成为开发新型疗法（如抗体激活剂和 CAR T 细胞）的重要基准。然而，进一步的研究对于确定和验证新的靶抗原至关重要，这些靶抗原可以提高疗效并扩大这些方法的临床适用性。
Immunotherapies in breast cancer: harnessing the cancer immunity cycle.
Introduction: Immunotherapies have found limited success in breast cancerdue to significant challenges within the tumor that block T-cell activity and function.
Areas covered: The current review discusses clinically relevant immunotherapeutics and trials within the framework of the cancer-immunity cycle.
Expert opinion: Current therapies such as antibody-drug conjugates and immune checkpoint blockade require proper biomarker selection, such as PD1 expression and the degree of tumor-infiltrating lymphocyte (TIL) infiltration to subset potential responders. HER2 and other tumor-associated antigens have served as valuable benchmarks for developing novel therapies, such as antibody engagers and CAR T-cells. However, further research is essential to identify and validate new target antigens that can enhance therapeutic efficacy and broaden the clinical applicability of these approaches.
期刊介绍：
The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials.
The Editors welcome:
Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development.
Articles should not include clinical information including specific drugs and clinical trials.
Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs.
The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
